Medigen ropes in new CRO partner for vaccine development in Taiwan

QPS, a global contract research organisation (CRO), has partnered with Taiwan-based Medigen Vaccine Biologics Corporation to complete the toxicology studies necessary to jump-start the development of a vaccine against COVID-19. Researchers at the Center for Toxicology and Preclinical Sciences (CTPS) in QPS Taiwan have quickly completed studies to accelerate the development of the vaccine, which has just been approved by the Taiwan Food and Drug Administration (TFDA) for the Authorisation of Emergency Use in Taiwan. Medigen Vaccine

Biologics Corporation has also been successful with a one-of-akind government grant for the clinical trial of the new vaccine. CTPS at QPS Taiwan has been the main testing facility to launch the toxicity study of the new vaccine. The researchers accepted the first clinical cases in October 2020 and completed the studies in just a few months. The team met all scientific objectives, analysing the endpoints and reporting on all results as scheduled.